Use of Transmucosal Ketamine in Post Stroke Depression

This open-label single-group study evaluates the feasibility and safety of transmucosal (sublingual) ketamine at 0.5 mg/kg administered twice, one week apart, in patients with post-stroke depression.

Primary aims are tolerability and feasibility; exploratory measures assess rapid antidepressant effects and safety signals to inform larger translational studies in the post-stroke population.